Japan PPI inflation slips to 11-mth low in July
On March 11, 2025, Claude Maraoui, the President and CEO of Journey Medical (TASE:BLWV) Corp (NASDAQ:DERM), a company whose stock has surged over 52% in the past year according to InvestingPro data, executed a sale of 49,271 shares of the company’s common stock. The transaction, which took place at an average price of $5.01 per share, totaled $246,847. This sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units, as per company policy. Following the transaction, Maraoui retains direct ownership of 2,003,147 shares, representing a significant portion of the company’s $104.45M market capitalization. With the company’s next earnings report due on March 20, 2025, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports, which cover over 1,400 US stocks.
In other recent news, Journey Medical Corporation announced the FDA approval of Emrosi™, a new treatment for moderate-to-severe papulopustular rosacea in adults. The approval follows successful results from two Phase 3 clinical trials, published in the Journal of the American Medical Association - Dermatology. These trials demonstrated that Emrosi™ met all primary and secondary endpoints, showing statistical superiority over existing treatments like Oracea® and placebo. The treatment, known as DFD-29, is a 40 mg Minocycline Hydrochloride Modified-Release Capsule, designed to be administered once daily for 16 weeks. The company plans to launch the product in early spring of 2025. The trials, named MVOR-1 and MVOR-2, reported significant success rates in reducing inflammatory lesions and achieving treatment goals. No significant safety issues were noted, with adverse events similar across all treatment groups. Journey Medical Corporation’s focus remains on marketing FDA-approved dermatological products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.